A post on the Telegram channel The General (@GeneralMCNews), which has 142,768 subscribers, said on Thursday at 10:08 a.m. Pacific time: "BREAKING: RFK Jr. moves to temporarily allow six experimental peptides to be sold by compounding pharmacies despite FDA scientists warning that their safety and benefits remain unproven." The post cited no source, but every factual part of it matches the public record. Health Secretary Robert F. Kennedy Jr. signed a notice, filed with the Federal Register on Wednesday, October 28, announcing a policy under which his department does not intend to take enforcement action against licensed pharmacies that compound six unapproved peptides while the Food and Drug Administration decides by rule whether to list them. FDA reviewers had recommended against listing any of the six for a July advisory meeting. HHS says newer manufacturing and usage data answer the reviewers' objections; its appendix does not include that data, no FDA staff assessment of it is public, and the Associated Press, citing six unnamed people, reports that FDA staff opposed this week's policy too. The post's "moves to" fits a draft still open for comment. What it leaves out is that the policy covers only individual prescriptions filled under set conditions, is not binding on HHS or the public, and works by not enforcing the law rather than by changing it.
Kennedy's policy says it will "discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients" and that it "advances patient choice and freedom while appropriately protecting patient safety." Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, called it a "more accountable alternative" for patients seeking gray-market peptides. Critics say it sidesteps drug approval: Dr. Robert Steinbrook of Public Citizen said Kennedy "has undermined the FDA and threatened public health," and Dr. Peter Lurie, a former FDA official who leads the Center for Science in the Public Interest, noted in the AP's report that the FDA has already approved rigorously tested drugs for insomnia, anxiety, inflammatory conditions and migraines, uses the peptides are promoted for online. An HHS spokesperson said the policy "does not grant FDA approval or establish clinical safety and effectiveness." This article is news, not medical advice.
The post, claim by claim
"RFK Jr. moves": confirmed. Kennedy signed the notice, which was issued by the HHS Office of the Secretary rather than the FDA, filed for public inspection on October 28, and is scheduled to appear in the Federal Register on Friday. It calls the policy a "draft" and takes comments for two weeks after publication, through November 13 according to CBS News. According to two of the people who discussed its development with the AP, HHS first wanted the FDA to write a regulation adding the peptides to the list of substances deemed safe for compounding, and changed course after FDA officials said agency scientists would not support one.
"Temporarily": confirmed, with no end date. The policy calls itself "interim" and lasts until each peptide "is addressed in a final rule as being included or not included on the 503A bulks list," the FDA's list of additional bulk ingredients pharmacies may compound with, beyond those covered by a U.S. Pharmacopeia standard or already used in an approved drug. CBS reported that the FDA has not yet proposed that rule. HHS says it may revisit the policy if "a safety signal or product quality issue arises."
"Six": confirmed. The policy lists BPC-157, epitalon, KPV, MOTS-c, semax and TB-500, the six that the FDA's Pharmacy Compounding Advisory Committee voted on July 23 and 24 to recommend adding to that list, by two or three votes each, according to a tally by the law firm McDermott Will & Schulte, which notes that the FDA "receives that vote as a recommendation it can accept, reject, or sit on for years." The panel rejected a seventh, emideltide. NPR reported that most of the eight members appointed ahead of the meeting have ties to the peptide industry; HHS said all underwent the standard ethics and vetting process.
"Experimental": a fair description. None of the six is FDA-approved, and HHS's own document uses the word: its testing table is titled "Acceptable orthogonal analytical methods to characterize and verify the properties of experimental peptides." FDA reviewers found no clinical studies of MOTS-c and no information on KPV or TB-500 given to people. HHS's appendix cites a placebo-controlled trial of a modified form of MOTS-c that reported no serious side effects, without identifying the trial, and semax records the FDA itself compiled, covering several hundred people who used it as a nasal spray. Those records include 451 children, and only one of the studies reported on side effects, finding none; the FDA reviewers concluded, "There is insufficient clinical information to characterize the safety profile of semax (free base) or semax acetate."
"Sold by compounding pharmacies": accurate, but narrower than it sounds. The policy covers only what federal law calls 503A compounding: state-licensed pharmacies, federal facilities and licensed physicians filling a prescription for a specific patient, not the larger 503B outsourcing facilities. To stay covered, pharmacies must use an ingredient from an FDA-registered manufacturer with a lab certificate of identity and purity, one peptide per product and only the listed routes, and must report serious side effects to the FDA. The AP reported that Lurie "pointed out that the FDA, under federal law, does not have the authority to enforce those pharmacy requirements." All six sat on the FDA's "Category 2" list of substances that "may present significant safety risks" from September 2023 until April 22, 2026; Kennedy confirmed their removal on April 15, after the original requesters withdrew their nominations, according to McDermott Will & Schulte. HHS says neither step changed their legal status, while McDermott describes Category 2 as a designation that "effectively prohibited their use in compounding."
"Despite FDA scientists warning that their safety and benefits remain unproven": confirmed. FDA staff reviews prepared for the July meeting reached that conclusion for all six. For BPC-157 the reviewers found "insufficient clinical safety information to characterize the safety profile" and "a lack of evidence to support the effectiveness" for ulcerative colitis. For KPV and TB-500 they cited "non-existing information on the use of these substances administered in humans." Each review ends: "Accordingly, we propose not adding" the peptide to the list. Those documented warnings date from July and addressed the permanent list. The AP's unnamed sources said FDA scientific staff also "had little input on the decision and opposed the changes" announced this week, though staff helped draft its safety conditions. HHS answers the reviews one by one, saying new certificates from FDA-registered makers supply test results the reviewers "found missing," that use is "now documented and quantified," and that the TB-500 concerns were "inferential rather than observed." Profoundd found no FDA staff assessment of that material on the committee's page or in news coverage.
What comes next
Comments close two weeks after Friday's publication. The Alliance for Pharmacy Compounding said details still need clarifying, including when the policy takes effect and how it fits with state pharmacy boards. NBC News reported that pharmacies "can start offering them now," and Time found telehealth sites advertising the six for $199 to $249 a month.
This article reflects reporting through the afternoon of Thursday, October 29, 2026. Sources: The General's Telegram post; the HHS Federal Register notice and policy with appendices; the FDA's July 23-24 advisory committee briefing documents and Category 2 list; the Associated Press, NPR (October 28 and July 23), CBS News, NBC News, The New York Times and Time, October 28; McDermott Will & Schulte, July 27.
